Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Assets (2021 - 2026)

bioAffinity Technologies has reported Assets over the past 6 years, most recently at $7.9 million for Q1 2026.

  • Quarterly Assets rose 43.23% to $7.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Mar 2026, up 43.23% year-over-year, with the annual reading at $11.0 million for FY2025, 68.27% up from the prior year.
  • Assets was $7.9 million for Q1 2026 at bioAffinity Technologies, down from $11.0 million in the prior quarter.
  • Over five years, Assets peaked at $14.1 million in Q3 2022 and troughed at $4.8 million in Q2 2025.
  • The 5-year median for Assets is $8.2 million (2023), against an average of $8.8 million.
  • Year-over-year, Assets skyrocketed 738.23% in 2022 and then plummeted 35.7% in 2024.
  • A 5-year view of Assets shows it stood at $12.2 million in 2022, then crashed by 32.51% to $8.2 million in 2023, then dropped by 20.77% to $6.5 million in 2024, then surged by 68.27% to $11.0 million in 2025, then decreased by 27.51% to $7.9 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Assets are $7.9 million (Q1 2026), $11.0 million (Q4 2025), and $11.5 million (Q3 2025).